Search results for "From ACP Journal Club"


 
Results 61 - 70 of about 131 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM

A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/09/10/7.htm
10 Sep 2021

BP-lowering drugs reduced major CV events by similar amounts in patients with and without type 2 diabetes

The results of a large meta-analysis support the conclusion that degree of blood pressure (BP) lowering, rather than the drug used, is the prime driver of cardiovascular (CV) risk reduction from hypertension therapy, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2022/12/09/9.htm
9 Dec 2022

In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y

A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.
https://diabetes.acponline.org/archives/2016/11/11/7.htm
11 Nov 2016

Intensive weight management in primary care improved weight loss and remission of type 2 diabetes

The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to reverse diabetes.
https://diabetes.acponline.org/archives/2018/04/13/8.htm
13 Apr 2018

In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization

If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/06/08/6.htm
8 Jun 2018

Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo

A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
https://diabetes.acponline.org/archives/2016/12/09/5.htm
9 Dec 2016

In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years

Despite the lack of observed benefit in this analysis, primary care physicians should continue to operate under the reasonable assumption that addressing cardiovascular (CV) risk factors improves longevity, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/05/08/6.htm
8 May 2020

In newly diagnosed type 2 diabetes mellitus, a Mediterranean diet (vs. a low-fat diet) delayed start of glucose-lowering drugs

Patients who were randomized to a low-carbohydrate Mediterranean diet shortly after type 2 diabetes diagnosis delayed their need for medication compared to those put on a low-fat diet in an Italian trial.
https://diabetes.acponline.org/archives/2014/10/10/5.htm
10 Oct 2014

Metformin reduced CV events compared with glipizide in patients with type 2 diabetes and CAD

A multicenter randomized controlled trial of Chinese patients with type 2 diabetes and coronary artery disease found that metformin reduced cardiovascular events more than glipizide at 5 years.
https://diabetes.acponline.org/archives/2013/05/10/10.htm
10 May 2013

Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD

Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/11/08/7.htm
8 Nov 2019

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next